Radiodermatitis - Pipeline Review, H2 2017

Radiodermatitis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H2 2017, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiodermatitis - Overview 6
Radiodermatitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Radiodermatitis - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Radiodermatitis - Companies Involved in Therapeutics Development0
Daiichi Sankyo Co Ltd0
FirstString Research Inc0
Foresee Pharmaceuticals LLC0
SK Chemicals Co Ltd1
viDA Therapeutics Inc1
Radiodermatitis - Drug Profiles2
cerium oxide - Drug Profile2
Product Description2
Mechanism Of Action2
R&D Progress2
FP-045 - Drug Profile3
Product Description3
Mechanism Of Action3
R&D Progress3
Granexin - Drug Profile4
Product Description4
Mechanism Of Action4
R&D Progress4
phenylbutyrate - Drug Profile6
Product Description6
Mechanism Of Action6
R&D Progress6
RS-9 - Drug Profile7
Product Description7
Mechanism Of Action7
R&D Progress7
SKI-2162 - Drug Profile8
Product Description8
Mechanism Of Action8
R&D Progress8
VTI-1000 Series - Drug Profile9
Product Description9
Mechanism Of Action9
R&D Progress9
ZM-241385 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Radiodermatitis - Dormant Projects 31
Radiodermatitis - Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List Of Tables

List of Tables
Number of Products under Development for Radiodermatitis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 20
Radiodermatitis - Pipeline by FirstString Research Inc, H2 2017 20
Radiodermatitis - Pipeline by Foresee Pharmaceuticals LLC, H2 2017 21
Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H2 2017 21
Radiodermatitis - Pipeline by viDA Therapeutics Inc, H2 2017 21
Radiodermatitis - Dormant Projects, H2 2017 31
Radiodermatitis - Discontinued Products, H2 2017 32